We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2
Read MoreHide Full Article
Cardiovascular Systems, Inc. reported a loss per share of 10 cents in second-quarter fiscal 2020 against earnings per share of a penny in the prior-year period. The reported figure was also wider than the Zacks Consensus Estimate of a loss of 3 cents.
Net Sales
Cardiovascular Systems’ revenues of $68.3 million in the fiscal second quarter marked a 13.5% year-over-year increase. Meanwhile, the top line beat the Zacks Consensus Estimate by 0.6%.
Segment Details
In the quarter under review, global Coronary device revenues jumped 30% year over year to $20.8 million, driven by 14%-unit growth in domestic atherectomy business, increased adoption of procedure support product portfolio and international expansion of orbital atherectomy, particularly in Japan.Domestic coronary revenues grew 22% to $18.5 million during the quarter.
Global peripheral revenue increased 8% to $47.6 million, primarily led by 12% unit growth in domestic atherectomy business. Domestic peripheral revenues increased 9% to $47.5 million.
Total U.S. revenues rose 13% to $66 million, while International revenues totaled around $2.4 million.
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise
Gross margin in the reported quarter was 79.9%, down 101 basis points (bps) year over year on a 19.5% rise in cost of goods sold.
Meanwhile, selling, general and administrative (SG&A) expenses rose 18.9% to $48.9 million plus research and development (R&D) expenses escalated 50.2% to $10.8 million. As a result, operating expenses increased 23.5% to $59.6 million. Operating loss in the reported quarter came in at $5 million against operating profit of $4.4 million a year ago.
Financial Position
The company exited second-quarter fiscal 2020 with cash and cash equivalents of $65.5 million, compared with $58.9 million at the end of first-quarter fiscal 2020.
2020 Outlook
Cardiovascular Systems raised the low end of its fiscal 2020 revenue guidance. The company projects revenues within $280 million to $283 million, compared with the previous guidance of $278-$283 million. This indicates 13% to 14% growth over fiscal 2019. The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at $280.8 million.
Moreover, the company reiterates gross profit margin at the band of 79-80%.
Our Take
We are upbeat about the year-over-year uptick in both global Coronary and peripheral device revenues during the quarter. The company is making concerted efforts in product innovation through R&D investments. The recently-launched next generation peripheral OAS with GlideAssist is another crucial highlight of the quarter. The recent FDA approval and launch of Viperwire Advance Coronary Guide Wire with Flex Tip instill optimism. On the flip side, operating loss and contraction of gross margin during the quarter are disappointing. Also, Cardiovascular Systems faces cut-throat competition in the niche space.
Earnings of Other MedTech Majors at a Glance
Cardiovascular Systems currently has a Zacks Rank of 3 (Hold).
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny, comparing favorably with the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
AmerisourceBergen reported first-quarter fiscal 2020 adjusted EPS of $1.76, which beat the Zacks Consensus Estimate of $1.67 by 5.4%. The Zacks Rank of 2 company has an expected long-term earnings growth rate of 7.4%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2
Cardiovascular Systems, Inc. reported a loss per share of 10 cents in second-quarter fiscal 2020 against earnings per share of a penny in the prior-year period. The reported figure was also wider than the Zacks Consensus Estimate of a loss of 3 cents.
Net Sales
Cardiovascular Systems’ revenues of $68.3 million in the fiscal second quarter marked a 13.5% year-over-year increase. Meanwhile, the top line beat the Zacks Consensus Estimate by 0.6%.
Segment Details
In the quarter under review, global Coronary device revenues jumped 30% year over year to $20.8 million, driven by 14%-unit growth in domestic atherectomy business, increased adoption of procedure support product portfolio and international expansion of orbital atherectomy, particularly in Japan.Domestic coronary revenues grew 22% to $18.5 million during the quarter.
Global peripheral revenue increased 8% to $47.6 million, primarily led by 12% unit growth in domestic atherectomy business. Domestic peripheral revenues increased 9% to $47.5 million.
Total U.S. revenues rose 13% to $66 million, while International revenues totaled around $2.4 million.
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise
Cardiovascular Systems, Inc. price-consensus-eps-surprise-chart | Cardiovascular Systems, Inc. Quote
Margin
Gross margin in the reported quarter was 79.9%, down 101 basis points (bps) year over year on a 19.5% rise in cost of goods sold.
Meanwhile, selling, general and administrative (SG&A) expenses rose 18.9% to $48.9 million plus research and development (R&D) expenses escalated 50.2% to $10.8 million. As a result, operating expenses increased 23.5% to $59.6 million. Operating loss in the reported quarter came in at $5 million against operating profit of $4.4 million a year ago.
Financial Position
The company exited second-quarter fiscal 2020 with cash and cash equivalents of $65.5 million, compared with $58.9 million at the end of first-quarter fiscal 2020.
2020 Outlook
Cardiovascular Systems raised the low end of its fiscal 2020 revenue guidance. The company projects revenues within $280 million to $283 million, compared with the previous guidance of $278-$283 million. This indicates 13% to 14% growth over fiscal 2019. The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at $280.8 million.
Moreover, the company reiterates gross profit margin at the band of 79-80%.
Our Take
We are upbeat about the year-over-year uptick in both global Coronary and peripheral device revenues during the quarter. The company is making concerted efforts in product innovation through R&D investments. The recently-launched next generation peripheral OAS with GlideAssist is another crucial highlight of the quarter. The recent FDA approval and launch of Viperwire Advance Coronary Guide Wire with Flex Tip instill optimism. On the flip side, operating loss and contraction of gross margin during the quarter are disappointing. Also, Cardiovascular Systems faces cut-throat competition in the niche space.
Earnings of Other MedTech Majors at a Glance
Cardiovascular Systems currently has a Zacks Rank of 3 (Hold).
Some better-ranked stocks, which reported solid results this earnings season, are Stryker Corporation (SYK - Free Report) , Accuray Incorporated (ARAY - Free Report) and AmerisourceBergen . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny, comparing favorably with the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
AmerisourceBergen reported first-quarter fiscal 2020 adjusted EPS of $1.76, which beat the Zacks Consensus Estimate of $1.67 by 5.4%. The Zacks Rank of 2 company has an expected long-term earnings growth rate of 7.4%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>